The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.
 
Thomas Urban Marron
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Boehringer Ingelheim; Celldex; DBV Technologies; Glenmark; NGM Biopharmaceuticals; Regeneron; Surface Oncology
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Patent on the combined use of IL4 blockade and PD-1 blockade. (Inst); Patient on the neoadjuvant use of cemiplimab for the treatment of HCC
Travel, Accommodations, Expenses - Abbvie; Genentech
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckenCall; Caremission; WCCT Global
Consulting or Advisory Role - Imaging Endpoints; Morphic Therapeutic; Qualigen Therapeutics; SpringWorks Therapeutics; Viracta Therapeutics
Research Funding - Advaxis (Inst); Agenus (Inst); Arcus Biosciences (Inst); BeiGene (Inst); BioLineRx (Inst); Blueprint Medicines (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Fujifilm (Inst); ImaginAb (Inst); Inanovate (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Nektar (Inst); Novita Pharmaceuticals (Inst); Syndax (Inst); Tolero Pharmaceuticals (Inst)
 
Christopher Chen
Consulting or Advisory Role - Boxer Capital; Globepoint Global
Research Funding - ADC Therapeutics (Inst); Gilead Sciences (Inst); Kinnate Biopharma (Inst); Mersana (Inst); ORIC Pharmaceuticals (Inst); Palleon Pharmaceuticals (Inst); Pionyr Therapeutics (Inst); Rain Oncology (Inst); Seagen (Inst); Takeda (Inst)
 
Jennifer Margaret Segar
No Relationships to Disclose
 
Ralph V. Boccia
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
Research Funding - Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Rigel (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Genentech; Incyte; Janssen; Rigel
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Ildiko Csiki
Employment - Riboscience
Stock and Other Ownership Interests - Coherus BioSciences; Geneos; Riboscience
Consulting or Advisory Role - Coherus BioSciences; Geneos
 
Juergen Schanzer
Consulting or Advisory Role - Riboscience
 
Ningwu Huang
Employment - Riboscience
Stock and Other Ownership Interests - Riboscience
 
Jeffrey Glen
Leadership - Eiger BioPharmaceuticals; Riboscience
Stock and Other Ownership Interests - Eiger BioPharmaceuticals; Riboscience
Consulting or Advisory Role - Eiger BioPharmaceuticals; Riboscience
 
Klaus Klumpp
Employment - Riboscience
Stock and Other Ownership Interests - Riboscience
Consulting or Advisory Role - Bioage
 
Jamal Ghazi Misleh
No Relationships to Disclose